Key Points
- Henry Schein director William Daniel bought 10,000 shares on May 11 at an average price of $69.19, totaling $691,900. After the purchase, he owned 20,000 shares, doubling his stake.
- The company recently beat quarterly earnings expectations, reporting EPS of $1.32 versus the $1.20 consensus, with revenue of $3.37 billion, up 6.3% year over year.
- Analysts currently have a Hold outlook on HSIC overall, with an average price target of $86.83, while institutional investors hold about 96.62% of the stock.
Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) Director William Daniel acquired 10,000 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Henry Schein Price Performance
Henry Schein stock opened at $69.35 on Wednesday. The firm has a market capitalization of $7.90 billion, a PE ratio of 20.95, a P/E/G ratio of 1.73 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The firm's 50-day simple moving average is $75.33 and its 200 day simple moving average is $75.17. Henry Schein, Inc. has a 52 week low of $61.94 and a 52 week high of $89.29.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.20 by $0.12. The company had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm's quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities research analysts predict that Henry Schein, Inc. will post 5.31 EPS for the current fiscal year.
Analyst Ratings Changes
HSIC has been the topic of a number of recent research reports. BTIG Research initiated coverage on shares of Henry Schein in a report on Thursday, April 16th. They issued a "neutral" rating on the stock. Wells Fargo & Company upped their target price on shares of Henry Schein from $76.00 to $87.00 and gave the company an "equal weight" rating in a report on Wednesday, February 25th. Weiss Ratings restated a "hold (c+)" rating on shares of Henry Schein in a report on Monday, May 4th. Leerink Partners restated a "market perform" rating on shares of Henry Schein in a report on Monday, March 9th. Finally, UBS Group restated a "neutral" rating and issued a $85.00 target price (down from $87.00) on shares of Henry Schein in a report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Henry Schein has an average rating of "Hold" and an average price target of $86.83.
Get Our Latest Report on HSIC
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein during the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein during the 2nd quarter worth approximately $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein during the 4th quarter worth approximately $30,000. Federated Hermes Inc. acquired a new stake in Henry Schein during the 4th quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Henry Schein during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 96.62% of the company's stock.
Henry Schein Company Profile
(
Get Free Report)
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
